{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000105","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.735564+00:00","generated_at":"2026-05-17T10:15:25.857722+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway","bullets":["FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.","Plans to submit U.S. IND in Q4 2025; patient dosing in Australia expected to start in Q4 2025.","U.S. enrollment expected to begin in Q1 2026 after IND clearance.","SER-252-1b study is randomized, double-blind, placebo-controlled Phase 1b with up to 88 patients.","CEO highlights capital-efficient 505(b)(2) pathway; platform may apply to other POZ-enabled small molecules."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000105","json":"https://secwatch.observer/filing/0001708599-25-000105.json","markdown":"https://secwatch.observer/filing/0001708599-25-000105.md","text":"https://secwatch.observer/filing/0001708599-25-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000105/0001708599-25-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000105/ser-20250825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:15:25.857722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}